Bristol-Myers’ Opdivo and Yervoy Combination Couldn’t Meet OS as Maintenance Therapy in esSCLC Patients Post 1L Chemo

 Bristol-Myers’ Opdivo and Yervoy Combination Couldn’t Meet OS as Maintenance Therapy in esSCLC Patients Post 1L Chemo

Bristol-Myers’ Opdivo and Yervoy Combination Couldn’t Meet OS as Maintenance Therapy in esSCLC Patients Post 1L Chemo

Shots:

  • The P-III Checkmate-451 involves assessing Opdivo (nivolumab, 1mg/kg) + Yervoy (ipilimumab,3 mg/kg) vs PBO as a maintenance therapy in patients with extensive-stage small cell lung cancer (SCLC)
  • The study demonstrated unmet 1EPs & 2EPs as OS with no new safety signals observed in patients
  • Opdivo is an PD-1 inhibitor indicated to treat multiple cancer and is currently approved in 65 countries including the US, EU Japan & China

Click here to read full press release/ article | Ref: Bristol-Myers | Image: Irishamerica

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post